Aurdan Capital Management LLC Makes New $5.42 Million Investment in Abbott Laboratories (NYSE:ABT)

Aurdan Capital Management LLC acquired a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 47,884 shares of the healthcare product maker's stock, valued at approximately $5,416,000. Abbott Laboratories comprises 2.1% of Aurdan Capital Management LLC's holdings, making the stock its 14th biggest position.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Redwood Park Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Noble Wealth Management PBC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. NewSquare Capital LLC grew its position in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after buying an additional 105 shares during the period. WealthTrak Capital Management LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at $28,000. Finally, Rialto Wealth Management LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock traded up $0.62 during midday trading on Friday, reaching $133.47. The stock had a trading volume of 1,176,077 shares, compared to its average volume of 6,109,033. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The firm's 50-day moving average price is $130.30 and its 200 day moving average price is $125.06. The firm has a market capitalization of $232.21 billion, a PE ratio of 17.43, a P/E/G ratio of 2.52 and a beta of 0.74. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. As a group, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on ABT. Citigroup lifted their price target on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Raymond James lifted their price objective on shares of Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a report on Thursday, April 17th. The Goldman Sachs Group lifted their price objective on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up from $133.00) on shares of Abbott Laboratories in a report on Thursday, April 17th. Finally, Morgan Stanley lifted their price objective on shares of Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $142.59.

Insider Transactions at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 949 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the transaction, the executive vice president now owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. The trade was a 1.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 95,278 shares of company stock valued at $12,745,859. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.